LU AA34893

Drug Profile

LU AA34893

Alternative Names: LU AA 34893

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lundbeck A/S
  • Class Antidepressants
  • Mechanism of Action Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bipolar disorders; Major depressive disorder

Most Recent Events

  • 04 Mar 2010 Lundbeck discontinues LU AA34893 development programme
  • 25 Nov 2009 Lundbeck is investigating preclinical findings in order to determine future development
  • 18 Nov 2009 Discontinued - Phase-II for Bipolar disorders in Asia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top